L'épidémiologie des maladies rénales - Société de néphrologie

More documents

Recommendations

Info

68 P. LANDAIS8. U.S. Re n a l Data Sy s t e m. 2006 Annual Data Report. Bethesda, MD, National Institutes ofHealth, National Institute of Diabetes and Digestive and Kidney Disease, 2006.9. Co r e s h J, Se lv in E, St e v e n s LA, et al. Prevalence of chronic kidney disease in the United States.JAMA, 2007 ; 298 : 2038-2047.10. Ha l l a n SI, Co r e s h J, As t o r BC, et al : International comparison of the relationship of chronickidney disease prevalence and ESRD risk. J Am Soc Nephrol,. 2006 ; 17 : 2275-2284.11. La n da i s P. Epidémiologie de la demande de soins pour l’insuffisance rénale terminale. PresseMed, 2002 ; 31 : 167-175.12. La n da i s P. Offre de soins et prévention de l’insuffisance rénale terminale. Presse Med, 2002 ; 31 :176-185.13. Ri s c h L, Sa e ly CH, Neyer U, et al. Prevalence of decreased glomerular filtration rate in patientsseeking non-nephrological medical care—an evaluation using IDMS-traceable creatinine basedMDRD as well as Mayo Clinic quadratic equation estimates. Clin Chim Acta,. 2007 ; 378 : 71-77.14. Be n a i n JP, Fa l l e r B, Br iat C, et al. Coût de la prise en charge de la dialyse en France NéphrolThér, 2007 ; 3 : 96-106.15. Rat c l i f f e PJ, Ph i l l i p s RE, Ol i v e r DO. Late referral for maintenance dialysis. Brit Med J,1984 ;288 : 441-443.16. Ju n g e r s P, Sk h i r i H, Zi n g r a f f J, et al. Bénéfices d’une prise en charge néphrologique précoceau cours de l’insuffisance rénale chronique. Presse Med, 1997 ; 26 : 1325-1329.17. Ka h n IH, Cat t o G, Ed w a r d N, et al. Death during the first 90 days of dialysis : a case controlstudy. Am J Kidney Dis, 1995 ; 25 : 276-280.18. Is m a il N, Ne y r a R, Ha k i m R. The medical and economical advantages of early referral of chronicrenal failure patients to renal specialists. Nephrol Dial Transplant, 1998 ; 13 : 246-250.19. Ch a n t r e l F, En a c h e I, Bo u i l l e r M, et al. Abysmal prognosis of patients with type 2 diabetesentering dialysis. Nephrol Dial Transplant, 1999 ; 14 : 129-136.20. Ju n g e r s P, Zi n g r a f f J, Al b o u z e G, et al. Late referral to maintenance dialysis : detrimentalconsequences. Nephrol Dial Transplant, 1993 ; 8 : 1089-1093.21. Ea d i n g t o n DW. Delayed referral for dialysis. Nephrol Dial Transplant, 1996 ; 11 : 2124-2126.22. Ob r a d o r GT, Pe r e i r a GJG. Early referral to the nephrologist and timely initiation of renalreplacement therapy : a paradigm shift in the management of patients with chronic renal failure.Am J Kidney Dis, 1998 ; 31 : 398-417.23. Kessler M, Fr im at L, Pa n e s c u V, Br ia n c o n S. Impact of nephrology referral on early and mid-termoutcomes in ESRD : EPidémiologie de l’Insuffisance REnale chronique terminale en Lorraine (EPIREL) :Results of a 2-year prospective, community-based study. Am J Kidney Dis, 2003 ; 42 : 474-485.24. Sesso R, Be l a s c o AG. Late diagnosis of chronic renal failure and mortality on maintenancedialysis. Nephrol Dial Transplant, 1996 ; 11 : 2417-2420.25. Aro r a P, Ob r a d o r GT, Ru t h a z e r R, et al. Prevalence, predictors, and consequences of latereferral at a tertiary care center. J Am Soc Nephrol, 1999 ; 10 : 1281-1286.26. La m e ir e N, Va n Bi e s e n W. The pattern of referral of patients with end-stage renal disease to thenephrologist—a european survey. Nephrol Dial Transplant, 1999 ; 14 : 16-23.27. Ju n g e r s P, Ch o u k ro u n G, Massy Z, et al. Epidemiology of end stage renal disease in the Ile-de-France area : a prospective study in 1998. Nephrol Dial Transplant, 2000 ; 15 : 2000-2006.28. Ju n g e r s P, Jo ly D, Ng u y e n-Kh o a T, et al. Continued late referral of patients with chronic kidneydisease. Causes, consequences, and approaches to improvement. Presse Med, 2006 ; 35 : 17-22.29. Hu i s m a n RM. The deadly risk of late referral. Nephrol Dial Transplant, 2004 ; 19 : 2175-2180.30. Pe r e i r a BJG. Optimization of pre-ESRD care : the key to improved dialysis outcomes. KidneyInt, 2000 ; 57 : 351-367.31. Fr im at L, Sie w e G, Lo o s-Ayav C, et al. Insuffisance rénale chronique : connaissanceset perception par les médecins généralistes. Nephrol Ther, 2006 ; 2 : 127-135.32. Ca m p b e l l JD, Ew i g m a n B, Ho s o k awa M, et al. The timing of referral of patients with end-stagerenal disease. Dial Transplant, 1989 ; 18 : 660-687.33. Bl e y e r AJ, Ro c c o MV, Bu r k a rt JM. The cost of hospitalisations due to hemodialysis accessmanagement. Nephrol Issues, 1995 ; 9 : 19-22.
L’ÉPIDÉMIOLOGIE DES MALADIES RÉNALES 6934. Ra p p o rt d u Ha u t Co n s e i l p o u r l’Av e n i r d e l’As s u r a n c e Ma l a d i e. Président, Mr B.Fragonard. Paris, La Documentation française, 23 janvier 2004. pp. 452. http ://www.securitesociale.fr/institutions/hcaam/rapport2004/rapport2004.htm35. Ra p p o rt a u ministre d e l a Sa n t é, d e l a Fa m i l l e e t d e s Pe r s o n n e s h a n d i c a p é e s. Président, MrAlain CORDIER. « Éthique et professions de santé », 2003. pp. 6436. Dur a n d-Za l e s k i I, Co m b e C, La n g P. International Study of Health Care Organization andFinancing for end-stage renal disease in France. Int J Health Care Fin Eco, 2007 ; 7 : 171-183.37. La n da i s P, Ri c h a r d JB, To u b i a na L et al. GIS and Health Care decision-making for End-StageRenal Disease. GEOMED2005. 15-16 sept 2005, Cambridge, UK. http ://www.geomed2005.org/sessions/38. Ri c h a r d JB, To u b i a na L, l e Mi g n ot L et al. SIGNe : A geographic information system on theWeb for end-stage renal disease. Stud Health Technol Inform, 2005 ; 116 : 713-718.39. Ri c h a r d JB, To u b i a na L, Le Mi g n ot L et al. A Web-based GIS for health care decision-support.AMIA Annu Symp Proc, 2005 : 365-369.40. Jac qu e l i n e t C, Co h e n S, No ë l C, La n da i s P. Pour une nouvelle stratégie de prélèvementd’organes : une priorité de santé publique. Med Ther, 1998 ; 4 : 589-593.41. Ra p p o rt a n n u e l-b i l a n d e s ac t i v i t é s d e l’ag e n c e d e b i o m é d e c i n e 2004 e t 2006. http ://www.agence-biomedecine.fr/fr/chiffres-principaux.aspx42. Ch a l e m Y, Ry c k e ly n c k JP, Tuppin P, et al. Access to, and outcome of, renal transplantation accordingto treatment modality of end-stage renal disease in France. Kidney Int, 2005 ; 67 : 2448-2453.43. Bayat S, Fr im at L, Th il ly N, et al. Medical and non-medical determinants of access to renaltransplant waiting list in a French community-based network of care. Nephrol Dial Transplant,2006 ; 21 : 2900-2907.44. Fu r b e r g CD, Pi t t B. Withdrawal of cerivastatin from the world market. Curr Control TrialsCardiovasc Med, 2001 ; 2 : 205-207.45. To p o l EJ. Failing the public health--rofecoxib, Merck, and the FDA. N Engl J Med, 2004 ; 351 :1707-1709.46. Mo n tag nac R, Bo f fa GA, Sc h i l l i n g e r F, Gu i l l au m i e J. Sensitization to recombinant humanerythropoietin in a woman under hemodialysis. Presse Med, 1992 ; 21 : 84-85.47. Ca s a d e va l l N, Nata f J, Vi ro n B et al. Pure red-cell aplasia and antierythropoietin antibodies inpatients treated with recombinant erythropoietin. N Engl J Med, 2002 ; 346 : 469-475.48. Rossert J, Ca s a d e va l l N, Ec k a r d t KU. Anti-erythropoietin antibodies and pure red cell aplasia.J Am Soc Nephrol, 2004 ; 15 : 398-406.49. Ve r h e l s t D, Rossert J, Ca s a d e va l l N, et al. Treatment of erythropoietin-induced pure red cellaplasia : a retrospective study. Lancet, 2004 ; 363 : 1768-1771.50. Ca s a d e va l l N, Co u r n oy e r D, Ma r s h J, et al. Recommendations on haematological criteria forthe diagnosis of epoetin-induced pure red cell aplasia. Eur J Haematol., 2004 ; 73 : 389-396.51. Be n n e t t CL, Lu m i na r i S, Nissenson AR, et al. Pure red-cell aplasia and epoetin therapy. N EnglJ Med., 2004 ; 351 : 1403-1408.52. Po l l o c k C, Jo h n s o n DW, Hö r l WH, et al. Pure red cell aplasia induced by erythropoiesisstimulatingagents. Clin J Am Soc Nephrol, 2008 ; 3 : 193-199.53. McKo y JM, St o n e c a s h RE, Co u r n oy e r D et al. Epoetin-associated pure red cell aplasia : past,present, and future considerations. Transfusion, 2008 ; 48 : 1754-1762.54. Be n n e t t CL, Co u r n oy e r D, Ca r s o n KR, et al. Long-term outcome of individuals with purered cell aplasia and antierythropoietin antibodies in patients treated with recombinant epoetin :a follow-up report from the Research on Adverse Drug Events and Reports (RADAR) Project.Blood, 2005 ; 106 : 3343-3347.55. Kr ä m e r I. Pharmacy and pharmacology of biosimilars. J Endocrinol Invest, 2008 ; 31 : 479-488.56. Je l k m a n n W. Recombinant EPO production-points the nephrologist should know. Nephrol DialTransplant, 2007 ; 22 : 2749-2753.57. Ke s s l e r M, Go l d s m i t h D, Sc h e l l e k e n s H. Immunogenicity of biopharmaceuticals. Nephrol DialTransplant., 2006 ; 21 (Suppl 5) : v9-12.
Page 1 and 2: L’épidémiologie des maladies r
Page 3 and 4: L’ÉPIDÉMIOLOGIE DES MALADIES R
Page 13: L’ÉPIDÉMIOLOGIE DES MALADIES R

L'épidémiologie des maladies rénales - Société de néphrologie

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?